Srikanth Damaraju, MD
Cardiovascular Disease · Corpus Christi, TXNPI 1790785442
Payments from drug & device makers
Across 637 payments — averaging $33.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Abbott$2K
- Abiomed$2K
- Edwards Lifesciences$2K
- W. L. Gore & Associates, Inc.$1K
- Johnson & Johnson$1K
- plus $4K from 26 others
What the payments were for
- Travel & lodging$6,19029%
- Food & beverage$15,02671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 302 | $7,786 |
| Abbott | 44 | $2,498 |
| Abiomed | 57 | $2,409 |
| Edwards Lifesciences | 9 | $1,571 |
| W. L. Gore & Associates, Inc. | 18 | $1,478 |
| Johnson & Johnson | 69 | $1,267 |
| Boston Scientific | 5 | $1,100 |
| Novartis | 19 | $398 |
| Pfizer | 22 | $365 |
| AstraZeneca | 16 | $288 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $285 |
| Shockwave Medical, Inc | 4 | $236 |
| Boehringer Ingelheim | 12 | $231 |
| Biotronik Inc. | 8 | $173 |
| Actelion Pharmaceuticals US, Inc. | 2 | $157 |
| Preventice Services, LLC | 1 | $127 |
| Cardiovascular Systems Inc. | 7 | $124 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Amgen | 5 | $80 |
| Merck | 5 | $76 |
| Silk Road Medical, Inc. | 1 | $73 |
| Endologix LLC | 1 | $69 |
| Philips North America LLC | 1 | $60 |
| Esperion Therapeutics, Inc. | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Angiodynamics, Inc. | 1 | $38 |
| Cvrx, Inc. | 2 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Cook Medical LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,317
- Watchman$1,066
- Mitra Clip system$1,028
- EVERA MRI XT DR SURESCAN$912
- Impella$862
- COREVALVE EVOLUT R$608
- GORE TAG Thoracic Branch Endoprosthesis$498
- GORE TAG Thoracic Endoprosthesis$422
- CARDIOMEMS$157
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$139
- MitraClip$123
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$122
- UPTRAVI$121
- OPSUMIT$121
- SYMPLICITY G3$121
- XARELTO$104
How this compares
$21,215 in reported general payments places this provider in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 680 | $702,770 |
| VyndamaxTafamidis | 14 | $520,333 |
| XareltoRivaroxaban | 136 | $143,585 |
| EntrestoSacubitril/Valsartan | 117 | $139,709 |
| Repatha SureclickEvolocumab | 80 | $71,112 |
| JardianceEmpagliflozin | 53 | $51,443 |
| BrilintaTicagrelor | 32 | $22,088 |
| Praluent PenAlirocumab | 37 | $18,154 |
| Metoprolol Succinate | 1,090 | $15,220 |
| FarxigaDapagliflozin Propanediol | 11 | $11,258 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $7,539 |
| ClopidogrelClopidogrel Bisulfate | 599 | $5,539 |
| Potassium Chloride | 363 | $5,527 |
| Atorvastatin Calcium | 620 | $5,397 |
| Nebivolol Hcl | 69 | $4,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $365 | $1,223,102694 claims |
| Johnson & JohnsonXarelto | $1,267 | $143,585136 claims |
| NovartisEntresto | $398 | $139,709117 claims |
| Boehringer IngelheimJardiance | $231 | $51,44353 claims |
| AstraZenecaBrilinta, Farxiga | $288 | $33,34643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Corpus Christi
- Travis TaylorCorpus Christi$676K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.